Pharmacological Characterization of the Novel Synthetic Cannabinoid Receptor Agonist 5F-EDMB-PICA and Its Effects on Body Weight in Rats
Authors: John Doe, Jane Smith, Richard Roe
Background: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of novel psychoactive substances with unpredictable pharmacological profiles. 5F-EDMB-PICA is a recently emerged indole-3-carboxamide SCRA. This study aimed to characterize its in vitro and in vivo pharmacology. Methods: In vitro, we assessed binding affinity and functional activity at human CB1 and CB2 receptors using radioligand binding and β-arrestin2 recruitment assays. In vivo, we evaluated the effects of acute and repeated administration of 5F-EDMB-PICA (0.3, 1, and 3 mg/kg, i.p.) on body weight, food intake, and core temperature in male Sprague-Dawley rats. Results: 5F-EDMB-PICA displayed high affinity (Ki = 0.5 nM) and potent agonist activity at CB1 (EC50 = 2.1 nM) and CB2 (EC50 = 18.3 nM). In vivo, it dose-dependently reduced body weight and food intake, and induced hypothermia. These effects were blocked by the CB1 antagonist rimonabant, confirming CB1-mediated action. Conclusions: 5F-EDMB-PICA is a potent CB1 agonist with in vivo effects similar to other SCRAs, highlighting its potential for abuse and toxicity. These findings contribute to the pharmacological characterization of emerging SCRAs and inform harm reduction strategies.
